Personalis (NASDAQ:PSNL) Price Target Cut to $8.50 by Analysts at HC Wainwright

Key Points

• Personalis (NASDAQ:PSNL) had its price target reduced from $9.00 to $8.50 by HC Wainwright, maintaining a "buy" rating, indicating potential upside from the current price.
• Other analysts, including Needham & Company and Guggenheim, have also issued buy ratings with targets of $7.00 and $6.00, respectively, showing a consensus outlook of "Buy" with an average target price of $7.58.
• Personalis reported a quarterly revenue of $17.20 million, which was below the consensus estimate, and is expected to post earnings of -1.4 EPS for the current fiscal year.

Personalis (NASDAQ:PSNL - Free Report) had its target price lowered by HC Wainwright from $9.00 to $8.50 in a research report sent to investors on Wednesday morning,Benzinga reports. The brokerage currently has a buy rating on the stock. HC Wainwright also issued estimates for Personalis' Q3 2025 earnings at ($0.30) EPS, Q4 2025 earnings at ($0.30) EPS, Q1 2026 earnings at ($0.28) EPS, Q2 2026 earnings at ($0.28) EPS, Q3 2026 earnings at ($0.22) EPS, Q4 2026 earnings at ($0.21) EPS, FY2026 earnings at ($0.98) EPS, FY2027 earnings at ($0.61) EPS, FY2028 earnings at ($0.29) EPS and FY2029 earnings at $0.10 EPS.

Several other brokerages also recently issued reports on PSNL. Guggenheim began coverage on Personalis in a research report on Thursday, May 15th. They issued a "buy" rating and a $6.00 price target on the stock. Needham & Company LLC reaffirmed a "buy" rating and issued a $7.00 price target on shares of Personalis in a research report on Thursday, April 10th. Six investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has an average rating of "Buy" and a consensus target price of $7.58.

Personalis Trading Down 0.9%

Personalis stock traded down $0.04 during mid-day trading on Wednesday, hitting $4.51. 1,154,123 shares of the company's stock were exchanged, compared to its average volume of 1,082,978. The stock has a market cap of $399.95 million, a P/E ratio of -3.52 and a beta of 1.86. Personalis has a 1-year low of $2.83 and a 1-year high of $7.79. The stock has a 50 day moving average of $6.09 and a two-hundred day moving average of $4.91.

Personalis (NASDAQ:PSNL - Get Free Report) last posted its earnings results on Tuesday, August 5th. The company reported ($0.23) EPS for the quarter, topping the consensus estimate of ($0.25) by $0.02. The firm had revenue of $17.20 million for the quarter, compared to the consensus estimate of $20.12 million. Personalis had a negative net margin of 113.70% and a negative return on equity of 47.57%. As a group, research analysts predict that Personalis will post -1.4 EPS for the current fiscal year.

Institutional Investors Weigh In On Personalis

A number of institutional investors have recently added to or reduced their stakes in the company. Royal Bank of Canada grew its position in Personalis by 3.2% during the first quarter. Royal Bank of Canada now owns 78,341 shares of the company's stock worth $275,000 after buying an additional 2,395 shares in the last quarter. China Universal Asset Management Co. Ltd. raised its stake in shares of Personalis by 18.2% in the first quarter. China Universal Asset Management Co. Ltd. now owns 17,704 shares of the company's stock valued at $62,000 after acquiring an additional 2,724 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. bought a new position in shares of Personalis in the fourth quarter valued at approximately $28,000. Stifel Financial Corp raised its stake in shares of Personalis by 25.0% in the fourth quarter. Stifel Financial Corp now owns 25,000 shares of the company's stock valued at $144,000 after acquiring an additional 5,000 shares during the last quarter. Finally, JPMorgan Chase & Co. increased its holdings in shares of Personalis by 2,827.0% in the fourth quarter. JPMorgan Chase & Co. now owns 5,854 shares of the company's stock valued at $34,000 after purchasing an additional 5,654 shares in the last quarter. 61.91% of the stock is owned by institutional investors and hedge funds.

Personalis Company Profile

Personalis, Inc develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection.